Last year, a wave of new products brought the industry succor as it awaits the full impact of the patent cliff on blockbuster brands. But companies should brace for contraction.
Company news: Elsevier, AstraZeneca, GSK
April 2, 2012
3:37 pm
Publisher Elsevier announced Monday that it will increase the number of papers it publishes for the Journal of Diabetes and Its Complications.
Novartis will eliminate 1,630 sales rep jobs and 330 headquarters marketing jobs as its hypertension franchise faces the impending loss of Diovan patent exclusivity and the impact of ugly study results on Tekturna sales.
Pfizer’s post-expiry plan for Lipitor: maximize brand’s sales
Pfizer said it plans not only to keep Lipitor consumer promotions running past the brand’s expiry later this month. It also aims to put an OTC version of the megablockbuster on the market at some point.
Brilinta boosts AstraZeneca, but can it carry them over the cliff?
The FDA gave the green light to AstraZeneca’s Brilinta (ticagrelor) anti-platelet for heart attack prevention, but the brand will carry a black box warning, a Risk Evaluation and Mitigation Strategy requirement and an obligation to educate doctors about possible risks of use in users of high-dose aspirin.
Pfizer sales up, as it braces for Lipitor down side
Pfizer reported higher fourth-quarter sales, but the world’s largest drug maker also revealed more downsizing and R&D cuts as it braces for the expiry of the Lipitor patent later this year.
Company news: Takeda and Teva
December 28, 2010
6:35 pm
Takeda granted generics firm Teva a license to market authorized copies in the US, starting Aug. 17, 2012, for best-selling diabetes pill Actos, and on Dec. 14, 2012, for Actoplus met (Actos plus metformin).
King Pharma resubmits abuse-resistant oxycodone to FDA
Two years after receiving a Complete Response letter from FDA about Remoxy, King Pharmaceuticals and Pain Therapeutics announced that they had resubmitted the drug for approval yesterday. A thumbs up or thumbs down from FDA is expected in June.
Ruling in FTC-Watson case may sway pay-for-delay debate in Senate
A US magistrate judge ruled that the Federal Trade Commission overstepped its authority when the agency tried to pressure a generic drug company to enter into a business deal with a competitor.